Navigation Links
Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
Date:2/27/2008

MELBOURNE, Australia, Feb. 27 /PRNewswire/ -- The Walter and Eliza Hall Institute of Medical Research (WEHI) announced today that Abbott, a global, broad-based, healthcare company, Genentech, a leading biotechnology company based in South San Francisco and WEHI have joined in a tripartite research collaboration to discover new anti-cancer drugs.

"This exciting three party research collaboration among world leaders in this field may increase the chance of translating basic scientific research in apoptosis, the process of programmed cell death, as carried out by our collaborators over recent years, into novel targeted cancer therapeutics," says Dr. Julian Clark, Head of Business Development at WEHI.

"We are excited to collaborate with Abbott and Genentech based on their expertise in apoptosis and strong track records in the development of small molecule drugs. We believe both will be excellent collaborators in bringing forward potential novel cancer therapeutics that target the apoptosis pathway," explains WEHI cancer researcher, Dr. David Huang.

Under the terms of the collaboration the three parties are engaged in a drug discovery research program, with Genentech and Abbott being responsible for the development, manufacturing and commercialization of potential new drugs. The discovery stage of the collaboration involves an integrated approach engaging research sites in South San Francisco, the Chicago area and Melbourne. Financial terms of the collaboration will not be disclosed.

WEHI's director, Professor Suzanne Cory, emphasizes that "WEHI's first priority is to work to ensure that cancer patients benefit from the results of our fundamental research and all three parties in the collaboration are committed to the discovery and development of improved cancer treatments that enable patients to live longer and healthier lives."

Further information:

Dr. Julian Clark

Head Business Development WEHI: +61-3-9345-2612;

jclark@wehi.edu.au

Brad Allan

Communications Manager WEHI: +61-3-9345-2345

Mob +61-403036116


'/>"/>
SOURCE Walter and Eliza Hall Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
2. Recovery Resources Collaborates with Two Nonprofit Agencies for Children of Alcoholics Outreach Program
3. MU researchers to collaborate on $20 million project
4. AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks with ADHD Medications
5. The American Pain Foundation (APF) and The HealthCentral Network Collaborate to Develop Enhanced Internet Resources for People with Pain
6. EHRVA Members Collaborate to Demonstrate Interoperability Success at NCHICA
7. Rosecrance and Chicagos Department of Environment Collaborate to Help Families Dispose of Unwanted Medicines and Drugs
8. CIDM Collaborates With World Congress to Advance Dialog on Online Provider Networks at WHIT 3.0
9. Free Access to Literature Data on Chagas Disease Offered Online: Collaborative Drug Discovery, Inc. provides Neglected Disease researchers with archive mine and collaborate access to small molecule bioactivity SAR data on parasitic disease
10. SAIC to Collaborate with UK Biometrics Institute
11. General Motors, Virginia Tech scientists collaborate to advance neuroinformatics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
(Date:10/12/2017)... ... , ... HMP , a leader in healthcare events and education, today announced ... Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie ... competition recognizes editorial and design excellence across a range of sectors. This year’s program ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/22/2017)... Md. , Sept. 22, 2017  As the ... Republican Senators Bill Cassidy (R-LA) and ... Information notes that the medical device industry is in ... medical device tax, the 2.3% excise tax on medical ... But they also want covered patients, increased visits and ...
(Date:9/19/2017)... a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed ...   ... Jim Bertolina, ... Tom Tefft ... medical device executive Josh Stopek , PhD, who has led R&D and business development ...
Breaking Medicine Technology: